A Trial of Tarlatamab in Patients With Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) and ECOG PS 2

START-lung is an international, multicentre, single-arm phase II trial. Protocol treatment consists of tarlatamab administered as an intravenous infusion until disease progression according to RECIST v1.1 criteria, unacceptable toxicity, or patient decision, whichever comes first. The primary objective of the trial is to assess the clinical efficacy of tarlatamab, in terms of 12-month OS rate, in patients with ES-SCLC and ECOG PS 2 who have previously received only one line of platinum-etoposide doublet chemotherapy with immune-checkpoint inhibition and whose disease has progressed.

NCT Number	NCT07203053
Lead Sponsor	ETOP IBCSG Partners Foundation Collaborators: Amgen
Conditions	Extensive Stage Lung Small Cell Cancer
Enrollment	48 participants
Start Date	2026-04-15
Primary Completion	2029-10 (estimated)
Study Completion	2029-10 (estimated)
Updated on ClinicalTrials.gov	2026-07-16